Tirzepatide for Obesity in Adults ≥ 65 Years: A Post Hoc Analysis of the SURMOUNT and SUMMIT Clinical Trials
Authors' conclusion
In this post hoc analysis from Phase 3 clinical trials, efficacy and safety profiles of tirzepatide in adults aged ≥ 65 years with obesity were comparable to those in adults aged < 65 years.
Study context
- Population
- Adults with obesity in the SURMOUNT-1 to −5 (incl. SURMOUNT-1 3-year), SURMOUNT-OSA and SUMMIT trials
- Comparison
- Tirzepatide in adults ≥65 years vs <65 years
Methodological detailsage subgroup analysis, pooled safety analysis
- Age subgroup analysis
- Pooled safety analysis
Primary result
As reported in the abstract
Efficacy by age subgroup · varying by trial design
- Tirzepatide associated with clinically meaningful weight reduction and favourable treatment differences in cardiometabolic risk factors and quality of life in adults ≥65 years, broadly comparable to adults <65 years
- Analysed by study
Safety
Adverse event (AEs) in older adults, tirzepatide vs placebo, and ≥65 vs <65 years · throughout treatment period
- No clinically meaningful differences in AE rates between tirzepatide and placebo in older adults for gastrointestinal tolerability, falls, fractures, depression, pancreatitis, and renal, hepatic, gallbladder and biliary-related AEs
- No clinically relevant risks beyond those inherent to older age in adults ≥65 vs <65 years
- Pooled population
Original publication
Tirzepatide for Obesity in Adults ≥ 65 Years: A Post Hoc Analysis of the SURMOUNT and SUMMIT Clinical Trials. Diabetes Obes Metab. Published 16 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →